BioNTech SE
(LTS:0A3M)
$
107.65
-1.25 (-1.15%)
Market Cap: 25.81 Bil
Enterprise Value: 7.53 Bil
PE Ratio: 0
PB Ratio: 1.23
GF Score: 63/100 
BioNTech SE at UBS Global Healthcare Virtual Conference Transcript
May 26, 2021 / 12:00PM GMT
Release Date Price:
$201.5
(+2.81%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Former Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutical
It's Navin Jacob. I'm a senior analyst covering SMID-cap biotech and large-cap pharma here at UBS. I'm happy to have with us BioNTech, our next presentation and Q&A session fireside chat. I will be hosting with Ryan Richardson from BioNTech, who is the Chief Strategy Officer. Ryan, welcome. Hope you're well.
Ryan Richardson
BioNTech SE - Chief Strategy Officer, MD & Member of Management Board
Thanks, Navin. Good to be with you.
Questions & Answers
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Former Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutical
Fantastic. So folks, we're going to have a little fireside chat presentation here with Ryan. And if you have questions, please don't be shy, please e-mail them in -- or rather, not e-mail them in. Just post them on this web chat here at the bottom of your
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers